Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.65 |
| ▸ | ABL1 | P00519 | 2/20 | 0.58 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381358 | 0.94 | CYP11B2 (0.60) | CYP11B2CYP11B1CYP19A1CYP17A1ABL1 | |
| SCHEMBL25304732 | 0.94 | CYP11B2 (0.60) | CYP11B2CYP11B1CYP19A1CYP17A1ABL1 | |
| SCHEMBL26260198 | 0.84 | CYP11B2 (0.88) | CYP11B2CYP11B1CYP19A1CYP17A1MKNK2 | |
| SCHEMBL14244848 | 0.83 | PDPK1 (0.62) | CYP11B2CYP11B1CYP19A1CYP17A1ABL1 | |
| SCHEMBL13304740 | 0.81 | CYP11B2 (0.71) | CYP11B2CYP11B1CYP19A1CYP17A1MKNK2 | |
| SCHEMBL14244842 | 0.81 | ABL1 (0.63) | ABL1DYRK1ADYRK1BPDPK1JAK2 | |
| SCHEMBL4510935 | 0.79 | CYP11B2 (1.00) | CYP11B2CYP11B1CYP19A1CYP17A1MKNK2 | |
| SCHEMBL27895115 | 0.79 | CYP11B2 (0.85) | CYP11B2CYP11B1CYP19A1CYP17A1MKNK2 | |
| SCHEMBL26565897 | 0.79 | CYP11B2 (0.85) | CYP11B2CYP11B1CYP19A1CYP17A1MKNK2 | |
| SCHEMBL26260221 | 0.79 | CYP11B2 (0.85) | CYP11B2CYP11B1CYP19A1CYP17A1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | claimed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | claimed |
| EP-2651899-B1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9206175-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8623889-B2 | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | GENENTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060262-A1 | Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof | XDH, CYP2B6, COX6B1 | CYP11B2 149/4885CYP11B1 168/4885CYP19A1 140/4885 |
| US-20120322785-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | CYP11B2 149/4885CYP11B1 168/4885CYP19A1 140/4885 |
| US-20140088076-A1 | SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF | XDH, CYP2B6, COX6B1 | CYP11B2 149/4885CYP11B1 168/4885CYP19A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.